AU5100201A - Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods ofuse thereof - Google Patents

Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods ofuse thereof

Info

Publication number
AU5100201A
AU5100201A AU5100201A AU5100201A AU5100201A AU 5100201 A AU5100201 A AU 5100201A AU 5100201 A AU5100201 A AU 5100201A AU 5100201 A AU5100201 A AU 5100201A AU 5100201 A AU5100201 A AU 5100201A
Authority
AU
Australia
Prior art keywords
isoforms
cloning
expression
sphingosine kinase
kinase type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU5100201A
Other languages
English (en)
Inventor
Sarah Spiegel
Takafumi Kohama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Georgetown University
Original Assignee
Sankyo Co Ltd
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd, Georgetown University filed Critical Sankyo Co Ltd
Publication of AU5100201A publication Critical patent/AU5100201A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU5100201A 2000-04-03 2001-03-26 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods ofuse thereof Pending AU5100201A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19431800P 2000-04-03 2000-04-03
US09/817,676 US6800470B2 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
PCT/US2001/009664 WO2001074837A1 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof

Publications (1)

Publication Number Publication Date
AU5100201A true AU5100201A (en) 2001-10-15

Family

ID=26889896

Family Applications (1)

Application Number Title Priority Date Filing Date
AU5100201A Pending AU5100201A (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods ofuse thereof

Country Status (9)

Country Link
US (4) US6800470B2 (enExample)
JP (1) JP4584525B2 (enExample)
KR (1) KR20020093017A (enExample)
AU (1) AU5100201A (enExample)
CA (1) CA2404965A1 (enExample)
DK (1) DK1268509T3 (enExample)
HU (1) HUP0301691A3 (enExample)
MX (1) MXPA02009781A (enExample)
WO (1) WO2001074837A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1268509T3 (da) * 2000-04-03 2010-03-08 Daiichi Sankyo Co Ltd Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
JP2005522999A (ja) * 2002-01-31 2005-08-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 癌を処置するための方法および組成物
WO2004035786A1 (en) * 2002-10-14 2004-04-29 Medvet Science Pty. Ltd. A method of modulating epithelial cell activity by modulating the functional levels of sphingosine kinase
AU2003292636A1 (en) * 2002-12-27 2004-07-29 The New Industry Research Organization Cell growth inhibitor using sphingosine kinase 2, method of constructing fused protein having its nuclear localization signal, method of screening drug candidate, and screening kit
US8372888B2 (en) * 2008-04-29 2013-02-12 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, compositions and processes for using same
US8314151B2 (en) 2008-04-29 2012-11-20 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, and processes for using same
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10675255B2 (en) 2017-06-23 2020-06-09 Enzo Bochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374616A (en) * 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
AU4097999A (en) * 1998-05-26 1999-12-13 Sarah Spiegel Sphingosine kinase, cloning, expression and methods of use
AU3828301A (en) * 2000-02-14 2001-08-27 Curagen Corp Novel sphingosine kinases
DK1268509T3 (da) * 2000-04-03 2010-03-08 Daiichi Sankyo Co Ltd Type 2 isoformer af sphingosin-kinase fra pattedyr, kloning, ekspression og fremgangsmåder til anvendelse deraf

Also Published As

Publication number Publication date
US7419814B2 (en) 2008-09-02
US6800470B2 (en) 2004-10-05
US7803595B2 (en) 2010-09-28
CA2404965A1 (en) 2001-10-11
JP2004500117A (ja) 2004-01-08
JP4584525B2 (ja) 2010-11-24
US20120107833A1 (en) 2012-05-03
US20020042101A1 (en) 2002-04-11
KR20020093017A (ko) 2002-12-12
MXPA02009781A (es) 2004-09-06
DK1268509T3 (da) 2010-03-08
US20040203104A1 (en) 2004-10-14
US8263349B2 (en) 2012-09-11
US20090169555A1 (en) 2009-07-02
WO2001074837A1 (en) 2001-10-11
HUP0301691A2 (hu) 2003-08-28
HUP0301691A3 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
HUP0101625A3 (en) New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
TWI315741B (en) A-isomaltosyltransferase, process for producing the same and use thereof
IL155500A0 (en) Stenoprophiluric matrices and methods for making and using the same
AU5752601A (en) Splice-region antisense composition and method
AU9112201A (en) Pulmonary delivery in treating disorders of the central nervous system
HUP0203746A3 (en) Novel composition and method for stabilizing the same
HUP0302772A3 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
AU7773001A (en) Acylacetonitriles, process for preparation thereof and miticides containing the same
EG23292A (en) Textile finishing composition and methods for using same.
AU2175302A (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method forproducing the same
HUP0202880A3 (en) Sustained release compositions, process for producing the same and use thereof
MXPA02003232A (es) Composiciones y metodos para alternar la expresion de genes.
AU5100201A (en) Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods ofuse thereof
AU2899900A (en) Cloned human sphingosine kinase homologues
ZA200307306B (en) Indolines, substituted in portion 6, and their use as kinase inhibitors.
AU3828301A (en) Novel sphingosine kinases
PL366168A1 (en) Impregnate, method for the production and use thereof
PL353214A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
AU5626900A (en) The high bone mass gene of 11q13.3
ZA200002546B (en) Sorbate-preserved compositions, method for the manufacture thereof and their use.
HUP0200476A3 (en) 1,3,4-oxadiazole derivatives and process for producing the same
HUP0301515A3 (en) Process for the preparation of chiral 1,4-diaryl-2-fluoro-2-butenes and their intermediates
FI973631L (fi) 1,3-diolipohjaiset eetterit, menetelmä 1,3-diolipohjaisten eetterien valmistamiseksi sekä eetterien käyttö
AU2002211600A1 (en) Gene expression profiling of antidepressant action in the brain
TW348475U (en) High chair which can be changed into normal chair